Latest Biotech News

The U.S. Food and Drug Administration has issued a complete response letter for PTC Therapeutics’ 15-lipoxygenase inhibitor, vatiquinone, intended for treating Friedreich’s ataxia, citing...

Biopharma industry leaders embrace AI-driven lab-in-the-loop workflows to consolidate compound design, ADME profiling, and compound management into unified, digitally enabled drug discovery...

Sarepta Therapeutics has activated a $100 million milestone payment to Arrowhead Pharmaceuticals following positive safety data in its SRP-1003 myotonic dystrophy program. To finance this, Sarepta...

The Scottish government has allocated £800,000 to deploy the Genedrive MT-RNR1 ID Kit across neonatal units to identify genetic risk for hearing loss caused by gentamicin antibiotic treatment....

Researchers at Zhejiang University have developed S²ALM, a Sequence-Structure multi-level pre-trained Antibody Language Model, an advanced AI framework to innovate antibody engineering. This model...

Viking Therapeutics reported mixed Phase 2 data for its GLP-1/GIP dual agonist oral obesity treatment, achieving target weight losses but encountering up to 38% discontinuation rates mainly due to...

Artificial intelligence is increasingly shaping healthcare interventions, from AI-driven models predicting pulmonary hemorrhage in preterm infants to digital therapeutics reducing suicide attempt...

Researchers from the University of California San Diego have developed a novel graphene-mediated optical stimulation method (GraMOS) to safely and effectively accelerate the maturation of human...

Rocket Pharmaceuticals has received FDA clearance to resume its Phase 2 gene therapy trial for Danon disease, a rare genetic disorder affecting multiple organs. The clinical hold issued in May,...

Viking Therapeutics’ oral weight loss drug VK2735 demonstrated statistically significant reductions in body weight in a Phase 2 trial, with up to 12.2% weight loss in 13 weeks. However,...

PTC Therapeutics’ vatiquinone, a candidate treatment for Friedreich’s ataxia, was rejected by the FDA due to insufficient evidence of efficacy. The agency requested a new, well-controlled study...

VantAI, a generative AI company specialized in programmable protein interactions, and Halda Therapeutics have announced a strategic research collaboration valued over $1 billion to accelerate...

Recent studies have unveiled novel insights into cancer biology including: the role of nerve injury-induced chronic inflammation in resistance to PD-1 immunotherapy; the metabolic interplay where...

Multiple pioneering efforts demonstrate how artificial intelligence and digital technologies are revolutionizing bioprocessing and pharmaceutical R&D. Ginkgo Bioworks launched a partnership...

Pediatric and neonatal healthcare are advancing through novel diagnostic and therapeutic technologies. AI models now predict pulmonary hemorrhage risk in preterm infants, improving neonatal...

The biotechnology industry in 2025 exhibits dynamic deal-making patterns with significant financing activities despite some challenges. Biopharma deal values have surged to record levels in the...

Researchers at the University of California San Diego have pioneered a graphene-mediated optical stimulation (GraMOS) technique that non-invasively accelerates the maturation of human brain...

Rocket Pharmaceuticals has received FDA clearance to restart its Phase 2 trial of RP-A501 gene therapy for Danon disease following a clinical hold due to a patient death. The trial will proceed...

Viking Therapeutics reported positive Phase 2 data for its oral GLP-1/GIP dual agonist VK2735, achieving weight loss up to 12.2% at 13 weeks. Despite reaching efficacy endpoints, a substantial...

Celldex Therapeutics announced it will cease development of barzolvolimab for eosinophilic esophagitis (EoE) despite meeting primary phase 2 endpoints related to mast cell depletion in the...